San Antonio Breast Cancer Symposium Posters2View(tm): Poster Number Index

Sponsored by

Poster Number Index

Click on one of the following number ranges below to display a list of posters. Click the checkbox next to each item to bookmark.
101 – 200 \| 201 – 300 \| 301 – 400 \| 401 – 500 \| 501 – 600 \| 601 – 700 \| 701 – 800 801 – 900 \| 901 – 1000 \| 1001 – 1100 \| 1101 – 1200 \| 2001 – 2100 \| 2101 – 2200 \| 3001 – 3100 3101 – 3200 \| 4001 – 4100 \| 4101 – 4200 \| 5001 – 5100 \| 5101 – 5200 \| 6001 – 6100 \| 6101 – 6152

[3101] Vitamin D and breast cancer incidence: a meta-analysis.

[3102] Is there consensus in the definition of endpoints in metastatic breast cancer?

[3103] Skin thickness as a measure of breast lymphedema.

[3104] Participation among breast cancer patients in a prospective cancer registry and quality of specimens collected for a tissue repository: the Expanded Breast Cancer Registry and Tissue Repository (EBCR) experience.

[3105] Feasibility trial of electro-acupuncture for aromatase inhibitor related arthralgia in breast cancer survivors.

[3106] A breast international group survey of young breast cancer patients' attitudes towards the risk of loss of fertility related to adjuvant therapies. EORTC protocol 10002 – BIG 3-98.

[3107] Factors that influence seeking second opinions, patient satisfaction, and education in breast cancer care: an internet-based study.

[3108] Adherence to endocrine therapy in women with breast cancer in a clinical practice setting.

[3109] BRCA testing in underserved women: a qualitative study of intepretations and impacts.

[3110] Analysis of factors associated with increased psychological distress in new outpatients at the breast clinic.

[3111] Out-of-pocket costs among women with breast cancer: data from the medical expenditure panel survey, 1996-2005.

[3113] Extended follow-up results from a prospective multi-center study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection, satisfaction, and anxiety.

[3114] The benefit using an integrated electronic trial platform for a neoadjuvant therapy trial (HEDON) in primary breast cancer – results of an evaluation study.

[3115] European and North American scientific meetings under review: presentation and subsequent publication of breast cancer related abstracts in peer-reviewed journals.

[3116] Sources of referral to early phase clinical trials: a case for putting all your eggs in one basket.

[3117] Incidence of postmenopausal symptoms and current mamagement: a survey of 260 breast cancer patients.

[3118] Phase II trial of dasatinib in triple-negative breast cancer: results of study CA180059.

[3119] RAD001 (everolimus) in combination with weekly paclitaxel and trastuzumab in patients with HER-2-overexpressing metastatic breast cancer with prior resistance to trastuzumab: a multicenter phase I clinical trial.

[3120] Therapeutic targeting of the c-fms oncogene diminishes the growth of breast cancer cells and ductal hyperplasia in the mammary gland of the CSF-1 transgenic mouse model.

[3121] A phase I, dose escalation study of lapatinib in combination with carboplatin, paclitaxel, with and without trastuzumab in patients with metastatic breast cancer.

[3122] Sequencing of type I IGF receptor (IGF1R) inhibition affects chemotherapy response in vitro and in vivo.

[3123] A phase II study to optimize dasatinib dosing in metastatic breast cancer patients using real-time pharmacodynamic tissue and urinary biomarkers.

[3124] Phase II study of weekly administration of docetaxel (D) in combination with the epidermal growth factor receptor (EGFR) inhibitor erlotinib (E) in metastatic breast cancer (MBC).

[3128] Molecular analysis of the selective pro-apoptotic effect of BN107 on estrogen receptor negative breast cancer cells.

[3129] Did survival of patients with distant metastasis from breast cancer improve during the last three decades? A cohort study on 4071 breast cancers.

[3130] Depression-anxiety and quality of life and the use of complementary and alternative medicine among breast cancer patients in Turkey.

[3131] Molecular marker correlates of clinical outcome in a phase II study of gefitinib or placebo in combination with anastrozole in postmenopausal women with hormone receptor-positive metastatic breast cancer.

[3132] Randomized phase III study of trastuzumab monotherapy followed by docetaxel and trastuzumab versus the combination of trastuzumab and docetaxel as first-line treatment in patients with HER2 positive metastatic breast cancer.

[3133] Final results from a phase II evaluation of lapatinib (L) and bevacizumab (B) in HER2-overexpressing metastatic breast cancer (MBC).

[3134] Circulating regulatory (CD4⁺CD25⁺FOXP3⁺) T cells decrease in breast cancer patients after vaccination with an Ii-Key-modified class II HER2/neu peptide (AE37).

[3135] Treatment with trastuzumab in recurrence free patients with early breast cancer and persistent disseminated tumor cells (DTC) in bone marrow.

[3137] A phase II study of ixabepilone plus trastuzumab for metastatic HER2-positive breast cancer.

[3138] Efficacy, safety and tolerability of dual monoclonal antibody therapy with pertuzumab + trastuzumab in HER2+ metastatic breast cancer patients previously treated with trastuzumab.

[3139] Optimal method of dosing HER2/neu peptide vaccines: U.S. Military Cancer Institute Clinical Trials Group Study 1-01, 1-02, 1-03, and 1-04.

[3140] Decrease in serum extracellular domain of HER2 at 4 and 8 weeks is associated with prolonged progression-free survival on lapatinib monotherapy.

[3141] Association between pathologic complete response and survival in patients treated with sequential anthracyclines and concomitant taxanes and trastuzumab in HER2-positive breast cancer.

[3143] A novel HER2 inhibitor TAK-285 overcomes trastuzumab resistance of HER2-over-expressing breast cancer.

[3144] Trastuzumab treatment in elderly patients with advanced breast cancer (ABC) – results from a large observational study.

[3145] Lapatinib (L) with weekly paclitaxel (P) as first-line therapy for patients (pts) with HER2+ metastatic breast cancer (MBC).

[3146] Correlation of tumor burden, liver and bone metastasis with serum extracellular domain HER2 expression in front-line metastatic breast cancer.

[3147] Baseline serum extracellular domain HER2 expression in hormone receptor-positive metastatic breast cancer: correlation with known tissue HER2 status.

[3148] Final results of a first line multicenter phase II metastatic breast cancer trial of vinflunine monotherapy and in combination with trastuzumab in HER2+ patients.

[3149] Phase II study of liposomal doxorubicin (Myocet®), docetaxel and trastuzumab combination as first line treatment of patients with her-2/neu positive locally advanced or metastatic breast cancer.

[3150] Trastuzumab 6 mg/kg and 4 mg/kg can be infused safely over 30 minutes.

[3151] Multicenter international phase II study of oral vinorelbine (NVBo), capecitabine (X) and trastuzumab (H) triple combination in HER2-positive metastatic breast cancer (MBC): updated results with a longer follow-up.

[3152] Treatment of infra-centimetric HER2-positive(+) invasive breast tumors. The Institut Curie experience.

[3153] Incidence of hormone-receptor negative and basal type breast tumors among HLA-A2⁺ patients and possible implications for cancer vaccine trials: U.S. Military Cancer Institute clinical trials group study I-01, I-02, I-03, and I-04.

[3154] Circulating tumor cell and endothelial cell data from a phase II evaluation of lapatinib and bevacizumab in HER2-overexpressing metastatic breast cancer.

[3155] HER2 and HER3 cooperatively regulate tumor cell growth and determine sensitivity to the HER kinase inhibitor TAK-285.

[3156] A multicenter phase II study of non-pegylated liposomal doxorubicin (MYOCET®) in combination with trastuzumab and docetaxel as first line therapy in metastatic breast cancer.

[3157] Lapatinib can restore capecitabine sensitivity in HER2-positive breast cancer.

[3158] Cardiac toxicity and adjuvant trastuzumab for breast cancer – the Cancer Centre of Southeastern Ontario experience.

[3159] HER2 positive early breast cancers: tumour demographics and trastuzumab therapy in the real-world.

[3160] Phase II trial of neoadjuvant 5-fluorouracil, epirubicin and cyclophosphamide (FEC100) followed by weekly paclitaxel and trastuzumab (PH) for HER2 positive breast cancer (Kinki Multidisciplinary Breast Oncology Group; KMBOG-0402).

Poster Sessions | Support | FAQ | Privacy Policy

San Antonio Breast Cancer Symposium
7703 Floyd Curl Dr. Mail Code 8224
San Antonio, TX 78229 USA
http://www.sabcs.org
Technical Support • © 2010 Marathon Multimedia, a Learner’s Digest International business. • All rights reserved